person · Reporting owner
Greenman William Mariner
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERUS CORPCERS · Entity 5431 | Director · President and CEO | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERUS CORP
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,053,036 |
Ending reported balance
After 2026-06-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-30 · Grant · Disposed 192,500 · Balance 5,154,955 Row 2 · 2026-06-30 · Sale · Disposed 101,919 · Balance 5,053,036 F1: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person. F2: Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $2.84 to $3.03 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person.
F2: Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $2.84 to $3.03 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHINOOK THERAPEUTICS, INC.
Report date August 11, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 23,643 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2024-09-14 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 3,600 · Balance 0 F2: This stock option award, which provided for ratable vesting in 12 monthly installments and vested in full on the one year anniversary of September 15, 2014, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.00 · Expires 2025-04-13 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 8,000 · Balance 0 F3: This stock option award, which provided for ratable vesting in 12 monthly installments and vested in full on the one year anniversary of March 30, 2015, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.10 · Expires 2026-06-08 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F4: This stock option award, which provided for ratable vesting in 4 quarterly installments band vested in full on the one year anniversary of June 9, 2016, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.75 · Expires 2027-06-07 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F5: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of June 8, 2017, was canceled for no consideration upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.00 · Expires 2028-06-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-11 · Disposition to issuer · Disposed 4,000 · Balance 0 F6: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of June 6, 2018, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2029-05-13 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-08-11 · Disposition to issuer · Disposed 6,000 · Balance 0 F7: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of May 14, 2019, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2030-05-04 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-08-11 · Disposition to issuer · Disposed 6,000 · Balance 0 F8: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of May 5, 2020, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-08-11 · Disposition to issuer · Disposed 23,522 · Balance 0 F9: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.81 · Expires 2031-06-03 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-08-11 · Disposition to issuer · Disposed 5,948 · Balance 0 F10: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-08-11 · Disposition to issuer · Disposed 13,300 · Balance 0 F10: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
F2: This stock option award, which provided for ratable vesting in 12 monthly installments and vested in full on the one year anniversary of September 15, 2014, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F3: This stock option award, which provided for ratable vesting in 12 monthly installments and vested in full on the one year anniversary of March 30, 2015, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F4: This stock option award, which provided for ratable vesting in 4 quarterly installments band vested in full on the one year anniversary of June 9, 2016, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F5: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of June 8, 2017, was canceled for no consideration upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F6: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of June 6, 2018, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F7: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of May 14, 2019, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F8: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of May 5, 2020, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F9: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F10: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 23:13 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 101,919 | $2.94 | $299,937.43 |
DisclosureSEC source: 0001377258-26-000008 · ownership.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,053,036 F1 · shares: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person. F2 · price: Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $2.84 to $3.03 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:13 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 192,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001377258-26-000008 · ownership.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,154,955 Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 23:44 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 447,757 | $1.66 | $742,022.90 |
DisclosureSEC source: 0001377258-26-000006 · ownership.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,998,493 F1 · shares: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person. F2 · price: Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.73 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 01:28 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 78,187 | $2.01 | $156,804.03 |
DisclosureSEC source: 0001377258-26-000004 · ownership.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,446,250 F1 · kind: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person. F2 · price: Represents a weighted average sales price. These shares were sold in a block trade per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold pursuant to such block trade. Read SEC document |
| March 05, 2026 Filed Mar 10, 2026 01:28 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 193,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001377258-26-000004 · ownership.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,524,437 Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:33 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 1,200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001377258-26-000002 · ownership.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,331,167 F1 · kind: Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest in two annual installments with 34% of the grant vesting on March 12, 2027, and 66% of the grant vesting on March 12, 2028, subject to the Reporting Person's continuous service to the Issuer through such vesting date. F2 · balance_after: Includes 5,318 and 10,004 shares purchased under Issuer's Employee Stock Purchase Plan on 08/29/25 and 02/27/26, respectively. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 21:00 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 122,827 | $1.45 | $178,099.15 |
DisclosureSEC source: 0000950170-25-040451 · ownership.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,115,845 F1 · kind: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person. F3 · price: Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $1.39 to $1.45 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 21:00 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 71,086 | $1.45 | $103,074.70 |
DisclosureSEC source: 0000950170-25-040451 · ownership.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,238,672 F1 · kind: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person. F2 · price: Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $1.39 to $1.47 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 23:55 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 60,984 | $1.50 | $91,354.03 |
DisclosureSEC source: 0000950170-25-036678 · ownership.xml · nonDerivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,309,758 F3 · kind: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person. F4 · price: Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $1.445 to $1.54 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 23:55 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 165,742 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-036678 · ownership.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,370,742 F2 · kind: Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. These RSUs were granted in payment of a portion of the 2024 annual bonus awarded to the Reporting Person and were fully vested upon grant, with no expiration date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 23:55 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 975,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-036678 · ownership.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,205,000 F1 · kind: Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest in two annual installments with 34% of the grant vesting on March 12, 2026, and 66% of the grant vesting on March 12, 2027, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 01:29 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 23,023 | $1.55 | $35,651.12 |
DisclosureSEC source: 0000950170-25-034075 · ownership.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,230,000 F4 · shares: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person. F5 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.49 to $1.59 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:29 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 57,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034075 · ownership.xml · derivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,637 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: Reflects restricted stock units earned upon satisfaction of certain performance criteria in connection with a performance-based award previously granted by the Issuer. F2 · derivative.expiration_date: Reflects restricted stock units earned upon satisfaction of certain performance criteria in connection with a performance-based award previously granted by the Issuer. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:29 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 57,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034075 · ownership.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,253,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Cerus Common Stock. F6 · balance_after: Includes 6,405 and 7,700 shares purchased under Issuer's Employee Stock Purchase Plan on 08/30/24 and 02/28/25. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:22 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 57,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-030165 · ownership.xml · derivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,637 Underlying: Common Stock · 57,637 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: Reflects restricted stock units earned upon satisfaction of certain performance criteria in connection with a performance-based award previously granted by the Issuer. F2 · derivative.expiration_date: Reflects restricted stock units earned upon satisfaction of certain performance criteria in connection with a performance-based award previously granted by the Issuer. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 01:30 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 63,611 | $2.02 | $128,195.25 |
DisclosureSEC source: 0001209191-24-004848 · doc4.xml · nonDerivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,181,281 F2 · shares: Represents shares sold pursuant to an instruction intended to comply with the requirements of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person. F4 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.935 to $2.04 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 01:30 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 62,315 | $2.06 | $128,181.96 |
DisclosureSEC source: 0001209191-24-004848 · doc4.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,244,892 F2 · shares: Represents shares sold pursuant to an instruction intended to comply with the requirements of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person. F3 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.025 to $2.10 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 12, 2024 Filed Mar 15, 2024 01:30 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 64,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-004848 · doc4.xml · derivative · entry 4 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F6 · price: Not applicable. F5 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2022. F5 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2022. Read SEC document |
| March 12, 2024 Filed Mar 15, 2024 01:30 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 64,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-004848 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,307,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:18 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit | 575,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004443 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,242,541 F1 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest in two annual installments with 1/3 of the grant vesting on March 12, 2025, and 2/3 of the grant vesting on March 12, 2026, subject to the Reporting Person's continuous service to the Issuer through such vesting date. F2 · balance_after: Includes 2,578 and 6,617 shares purchased under Issuer's Employee Stock Purchase Plan on 08/31/23 and 02/29/24, respectively. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:08 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,300 | $26.12 Strike: $13.88 | $347,396.00 |
DisclosureSEC source: 0001209191-23-045420 · doc4.xml · derivative · entry 11 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,300 shares Expires 2032-05-25 F10 · derivative.exercise_date: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:08 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,948 | $23.19 Strike: $16.81 | $137,934.12 |
DisclosureSEC source: 0001209191-23-045420 · doc4.xml · derivative · entry 10 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,948 shares Expires 2031-06-03 F10 · derivative.exercise_date: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:08 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,522 | $25.23 Strike: $14.77 | $593,460.06 |
DisclosureSEC source: 0001209191-23-045420 · doc4.xml · derivative · entry 9 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,522 shares Expires 2030-10-05 F9 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:08 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | $25.00 Strike: $15.00 | $150,000.00 |
DisclosureSEC source: 0001209191-23-045420 · doc4.xml · derivative · entry 8 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2030-05-04 F8 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of May 5, 2020, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:08 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | $23.55 Strike: $16.45 | $141,300.00 |
DisclosureSEC source: 0001209191-23-045420 · doc4.xml · derivative · entry 7 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2029-05-13 F7 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of May 14, 2019, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:08 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,000 | $7.00 Strike: $33.00 | $28,000.00 |
DisclosureSEC source: 0001209191-23-045420 · doc4.xml · derivative · entry 6 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2028-06-05 F6 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of June 6, 2018, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:08 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,600 | $0.00 Strike: $52.75 | $0.00 |
DisclosureSEC source: 0001209191-23-045420 · doc4.xml · derivative · entry 5 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires 2027-06-07 F5 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of June 8, 2017, was canceled for no consideration upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:08 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,600 | $0.00 Strike: $62.10 | $0.00 |
DisclosureSEC source: 0001209191-23-045420 · doc4.xml · derivative · entry 4 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires 2026-06-08 F4 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 4 quarterly installments band vested in full on the one year anniversary of June 9, 2016, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:08 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $85.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045420 · doc4.xml · derivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2025-04-13 F3 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 12 monthly installments and vested in full on the one year anniversary of March 30, 2015, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:08 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,600 | $35.00 Strike: $5.00 | $126,000.00 |
DisclosureSEC source: 0001209191-23-045420 · doc4.xml · derivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires 2024-09-14 F2 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 12 monthly installments and vested in full on the one year anniversary of September 15, 2014, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:08 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerCommon Stock | 23,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045420 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. Read SEC document |
| May 30, 2023 Filed May 31, 2023 19:26 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 1,155 | $23.30 | $26,911.50 |
DisclosureSEC source: 0001209191-23-033191 · doc4.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,643 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-l trading plan previously adopted by the Reporting Person and represent shares by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 26, 2023 Filed May 31, 2023 19:26 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033191 · doc4.xml · derivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: 100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date. F4 · derivative.expiration_date: 100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date. Read SEC document |
| May 26, 2023 Filed May 31, 2023 19:26 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033191 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 23:47 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 22,732 | $2.80 | $63,649.60 |
DisclosureSEC source: 0001209191-23-018683 · doc4.xml · nonDerivative · entry 4 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,658,346 F2 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the election to satisfy the minimum statutory tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. F3 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.74 to $3.03 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 23:47 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 37,748 | $2.80 | $105,694.40 |
DisclosureSEC source: 0001209191-23-018683 · doc4.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,616,411 F2 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the election to satisfy the minimum statutory tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. F3 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.74 to $3.03 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 23:47 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 64,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018683 · doc4.xml · derivative · entry 6 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,666 Underlying: Common Stock · 64,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F5 · price: Not applicable. F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2022. F6 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2022. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 23:47 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 107,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018683 · doc4.xml · derivative · entry 5 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F5 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit vests 33% on March 12, 2021, 33% on March 12, 2022 and 34% on March 12, 2023. F4 · derivative.expiration_date: The restricted stock unit vests 33% on March 12, 2021, 33% on March 12, 2022 and 34% on March 12, 2023. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 23:47 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 64,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018683 · doc4.xml · nonDerivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,681,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 23:47 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 107,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018683 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,654,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:17 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit | 575,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015762 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,546,634 F1 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vests in three equal annual installments beginning on March 12, 2024, subject to the Reporting Person's continuous service to the Issuer through such vesting date. F2 · balance_after: Includes 4,442 shares purchased under Issuer's Employee Stock Purchase Plan on 02/28/23, respectively. Read SEC document |
| May 26, 2022 Filed May 31, 2022 18:16 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantRestricted Stock Unit · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032945 · doc4.xml · derivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 Underlying: Common Stock · 3,300 shares Expires 2023-05-26 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: 100% of the RSUs will vest on May 26, 2023, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| May 26, 2022 Filed May 31, 2022 18:16 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 13,300 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-22-032945 · doc4.xml · derivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2032-05-25 F1 · derivative.exercise_date: 100% of the stock option will vest on May 26, 2023, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 02:00 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 33,276 | $5.04 | $167,697.73 |
DisclosureSEC source: 0001209191-22-019066 · doc4.xml · nonDerivative · entry 6 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,967,192 F2 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the election to satisfy the minimum statutory tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. F3 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.871 to $5.22 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 02:00 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 53,702 | $5.04 | $270,631.23 |
DisclosureSEC source: 0001209191-22-019066 · doc4.xml · nonDerivative · entry 4 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,935,801 F2 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the election to satisfy the minimum statutory tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. F3 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.871 to $5.22 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 02:00 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 78,043 | $5.04 | $393,305.50 |
DisclosureSEC source: 0001209191-22-019066 · doc4.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,885,141 F2 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the election to satisfy the minimum statutory tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. F3 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.871 to $5.22 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 12, 2022 Filed Mar 16, 2022 02:00 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 64,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-019066 · doc4.xml · derivative · entry 9 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,333 Underlying: Common Stock · 64,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F5 · price: Not applicable. F7 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2022. F7 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2022. Read SEC document |
| March 12, 2022 Filed Mar 16, 2022 02:00 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 104,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-019066 · doc4.xml · derivative · entry 8 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,525 Underlying: Common Stock · 104,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F5 · price: Not applicable. F6 · derivative.exercise_date: The restricted stock unit vests 33% on March 12, 2021, 33% on March 12, 2022 and 34% on March 12, 2023. F6 · derivative.expiration_date: The restricted stock unit vests 33% on March 12, 2021, 33% on March 12, 2022 and 34% on March 12, 2023. Read SEC document |
| March 12, 2022 Filed Mar 16, 2022 02:00 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 151,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-019066 · doc4.xml · derivative · entry 7 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 151,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F5 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit vests 33% on March 12, 2020, 33% on March 12, 2021 and 34% on March 12, 2022. F4 · derivative.expiration_date: The restricted stock unit vests 33% on March 12, 2020, 33% on March 12, 2021 and 34% on March 12, 2022. Read SEC document |
| March 12, 2022 Filed Mar 16, 2022 02:00 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 64,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-019066 · doc4.xml · nonDerivative · entry 5 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.